MAPKAPK2

Across TCGA pan-cancer cohorts, MAPKAPK2 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated MAPKAPK2 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MAPKAPK2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAPKAPK2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

COAD, UCEC, and GBM are the cancer types where MAPKAPK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	0.908	1.000	.009	108	view →
UCEC	OS	Median	II,III,IV	0.620	1.000	.011	24	view →
GBM	DFS	Quartile	All	0.220	0.525	<.001	15	view →
LSCC	DFS	Median	II,III,IV	0.520	0.831	.008	3	view →
LUAD	OS	Median	III,IV	0.750	0.997	.031	3	view →
HNSC	OS	Tertile	III,IV	0.575	0.810	.028	2	view →
PDAC	DFS	Tertile	II,III,IV	0.500	0.327	.032	2	view →
CCRCC	OS	Tertile	All	0.652	1.000	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MAPKAPK2–COAD (DFS)

Open the COAD breakdown →